Drugs / FATE-NK100
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03319459 | Jan 2018 → May 2020 | HER2 positive breast carcinoma, colorectal cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma +4 | Fate Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03213964 | Oct 2017 → Mar 2021 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT03081780 | Apr 2017 → Aug 2020 | acute myeloid leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2018-11-11 | Fate Therapeutics | Results Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500 fatetherapeutics.com ↗
As of a October 22, 2018 data cutoff, one-month follow-up data were available on fourteen subjects 1 , with clinical benefit indicated in seven of these fourteen subjects: |
| 2018-05-10 | Fate Therapeutics | Results Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress fatetherapeutics.com ↗
We have observed safety, persistence and anti-tumor activity with NK100 in initial Phase 1 dose escalation against solid and liquid tumors. |
| 2018-03-29 | Fate Therapeutics | Results Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018 fatetherapeutics.com ↗
Additionally, the Day 28 response evaluation for Subject 2 following a single intraperitoneal infusion of NK100 showed stable disease with evidence of tumor reduction. |
| 2017-11-10 | Fate Therapeutics | Results Fate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for Relapsed / Refractory Acute Myelogenous Leukemia at SITC 2017 Annual Meeting fatetherapeutics.com ↗
Anti-leukemia activity was observed with FATE-NK100, the Company's first-in-class adaptive memory natural killer (NK) cell cancer immunotherapy, in each of the treated dose cohorts of the VOYAGE study. |
| 2017-08-14 | Fate Therapeutics | Regulatory Fate Therapeutics Reports Second Quarter 2017 Financial Results fatetherapeutics.com ↗
FDA Clears Investigational New Drug Applications for FATE-NK100 in Recurrent Ovarian Cancer and in Advanced Solid Tumors with Monoclonal Antibody Therapy |
| 2017-08-08 | Fate Therapeutics | Results Fate Therapeutics Announces Publication of Preclinical Data in Cancer Research and FDA Clearance of Third IND for FATE-NK100 fatetherapeutics.com ↗ |
| 2017-05-10 | Fate Therapeutics | Regulatory Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors fatetherapeutics.com ↗
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company's investigational new drug (IND) application for FATE-NK100 in advanced solid tumors. |
| 2017-03-13 | Fate Therapeutics | Regulatory Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy fatetherapeutics.com ↗
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application for FATE-NK100, the Company's first-in-class adaptive memory natural killer (NK) cell product candidate. |
| 2017-03-02 | Fate Therapeutics | Results Fate Therapeutics to Highlight Natural Killer Cell Programs and Engineered Pluripotent Cell Platform for Off-the-Shelf Cancer Immunotherapy at the 2017 AACR Annual Meeting fatetherapeutics.com ↗
Enhanced cytotoxicity in vivo in a SKOV-3 (human ovarian cancer cell line) xenogeneic adoptive transfer model; |
All press releases naming this drug 12 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FATE-NK100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03319459 ↗ |
| Modality | Cell therapy | “FATE-NK100 is a natural killer (NK) cell product” NCT03081780 ↗ |
| Route | Other | “via intra-peritoneal catheter” NCT03213964 ↗ |